John Overdeck’s Novavax NVAX Stock Holding History

John Overdeck’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53,500	Closed	-$371K	–	3191
2023 Q1	$371K	Buy	+53,500	New	+$492K	﹤0.01%	2329

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

John Overdeck's NVAX Position: Q2 2026 in Review

John Overdeck increased its Novavax (NVAX) stake by 565% in Q2 2026, buying an estimated $31.1M and bringing the position to 4,091,043 shares worth $38.5M. The position accounts for 0.03% of the portfolio, ranked #682.

John Overdeck first reported a position in NVAX in Q3 2013 and has held it in 23 quarters since. 264 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

John Overdeck held 4,091,043 shares of Novavax worth $38.5M as of Q2 2026.
John Overdeck bought 3,476,244 Novavax shares in Q2 2026, an estimated $31.1M.
Novavax made up 0.03% of John Overdeck's portfolio in Q2 2026, its #682 holding.
John Overdeck first reported a position in Novavax in Q3 2013 and has held it in 23 quarters since.
264 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.